Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc.CRBP · Entity 6261 | Director | May 20, 2020 | May 22, 2020 |
| Motus GI Holdings, Inc.MOTS · Entity 93100 | Director · Chairman of the Board | February 10, 2022 | February 11, 2022 |
| NAKED BRAND GROUP INC.NAKD · Entity 166704 | Director · 10% owner | January 12, 2017 | March 15, 2017 |
| Orchestra BioMed Holdings, Inc.OBIO · Entity 434 | Director · See Remarks | September 10, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Corbus Pharmaceuticals Holdings, Inc.
Report date May 20, 2020 · Filed May 22, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.30 · Expires 2030-05-20 | Direct | 40,500 |
Reported balance
After 2020-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-20 · Grant · Acquired 40,500 · Balance 40,500 F1: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant.
Motus GI Holdings, Inc.
Report date February 10, 2022 · Filed February 11, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.46 · Expires 2032-02-10 | Direct | 50,000 |
Reported balance
After 2022-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-02-10 · Grant · Acquired 50,000 · Balance 50,000 F1: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). The option becomes exercisable as to 100% of the shares on February 10, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's 2016 Equity Incentive Plan (the "2016 Plan"). The option becomes exercisable as to 100% of the shares on February 10, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2016 Plan.
NAKED BRAND GROUP INC.
Report date January 12, 2017 · Filed March 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2021-03-13 | IndirectBy Carole S. Hochman Trust | 1,200,000 |
Reported balance
After 2017-03-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-13 · Grant · Acquired 1,200,000 · Balance 1,200,000 F1: The reporting person and an immediate family member are beneficiaries of the Carole S. Hochman Trust. The reporting person is also one of two trustees of the Carole S. Hochman Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person and an immediate family member are beneficiaries of the Carole S. Hochman Trust. The reporting person is also one of two trustees of the Carole S. Hochman Trust.
Orchestra BioMed Holdings, Inc.
Report date September 10, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per share ("Common Stock")SEC Table I · non-derivative | Direct | 1,067,463 |
Reported balance
After 2026-09-10 transaction · row 1
1 source rowRow 1 · 2026-09-10 · Tax withholding · Disposed 3,283 · Balance 1,067,463 F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. |
| Common StockSEC Table I · non-derivative | IndirectBy the DPH 2008 Trust | 432,916 |
Reported balance
After 2026-09-10 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-10 · Tax withholding · Disposed 3,283 · Balance 432,916 F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations. |
| Common StockSEC Table I · non-derivative | IndirectBy the Solomon Ascher Hochman 2019 Trust | 2,000 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,000 |
| Common StockSEC Table I · non-derivative | IndirectBy the Hannah Hochman 2019 Trust | 2,000 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,000 |
| Common StockSEC Table I · non-derivative | IndirectBy the Judah Herman Hochman 2019 Trust | 2,000 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 2,000 |
| Common StockSEC Table I · non-derivative | IndirectBy the NSH 2008 Family Trust | 3,140 |
Reported balance
Holding disclosure · report date 2026-09-10 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 3,140 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the withholding of shares by the Issuer to satisfy tax withholding obligations in connection with vesting of restricted stock units ("RSUs"). No shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | OtherWarrants (right to buy) · Derivative | 115,997 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · derivative · entry 13 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By Orchestra MOTUS Co-Investment Partners, LLC Disclosed balance after: 115,997 Underlying: Common Stock · 115,997 shares Expires 2023-02-16 F7 · kind: The securities were acquired as consideration for entering into one or more agreements in connection with Company's initial public offering. Please see the Registration Statement for a complete description of the warrant terms and such agreements. F3 · ownership.nature: The securities are directly held by Orchestra MOTUS Co-Investment Partners, LLC ("OMCP"). Orchestra Medical Ventures, LLC ("OMV LLC") serves as managing member to OMCP. Reporting Person and Darren Sherman are the managing partners of OMV LLC. Reporting Person, together with Mr. Sherman, jointly exercises sole dispositive and sole voting power over the shares owned by OMCP. Each of Reporting Person, Mr. Sherman and OMV LLC disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934 ("Section 16"), beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Reporting Person, Mr. Sherman or OMV LLC is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | OtherWarrants (right to buy) · Derivative | 106,980 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · derivative · entry 12 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By Orchestra Medical Ventures II, L.P. Disclosed balance after: 106,980 Underlying: Common Stock · 106,980 shares Expires 2023-02-16 F7 · kind: The securities were acquired as consideration for entering into one or more agreements in connection with Company's initial public offering. Please see the Registration Statement for a complete description of the warrant terms and such agreements. F2 · ownership.nature: The securities are directly held by Orchestra Medical Ventures II, L.P. ("OMV II"). Orchestra Medical Ventures II GP, LLC ("OMV GP") serves as general partner to OMV II. Reporting Person and Darren Sherman are the managing members of OMV GP. Reporting Person, together with Mr. Sherman, jointly exercises sole dispositive and sole voting power over the shares owned by OMV II. Each of Reporting Person, Mr. Sherman and OMV GP disclaims, for purposes of Section 16, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Reporting Person, Mr. Sherman or OMV GP is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | OtherWarrants (right to buy) · Derivative | 300 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · derivative · entry 11 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires 2023-02-16 F7 · kind: The securities were acquired as consideration for entering into one or more agreements in connection with Company's initial public offering. Please see the Registration Statement for a complete description of the warrant terms and such agreements. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | ConversionSeries A Convertible Preferred Stock · Derivative | 65,038 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · derivative · entry 10 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By Orchestra MOTUS Co-Investment Partners, LLC Disclosed balance after: 0 Underlying: Common Stock · 65,038 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock is immediately convertible, at the option of the Reporting Person, into one share of common stock, par value $0.0001 per share (the "Common Stock"), of Motus GI Holdings, Inc. ("Motus"), and shall convert into Common Stock upon the occurrence of certain events. Please see the Motus Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-222441) (the "Registration Statement") for a complete description of the conversion rights. F6 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock is immediately convertible, at the option of the Reporting Person, into one share of common stock, par value $0.0001 per share (the "Common Stock"), of Motus GI Holdings, Inc. ("Motus"), and shall convert into Common Stock upon the occurrence of certain events. Please see the Motus Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-222441) (the "Registration Statement") for a complete description of the conversion rights. F3 · ownership.nature: The securities are directly held by Orchestra MOTUS Co-Investment Partners, LLC ("OMCP"). Orchestra Medical Ventures, LLC ("OMV LLC") serves as managing member to OMCP. Reporting Person and Darren Sherman are the managing partners of OMV LLC. Reporting Person, together with Mr. Sherman, jointly exercises sole dispositive and sole voting power over the shares owned by OMCP. Each of Reporting Person, Mr. Sherman and OMV LLC disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934 ("Section 16"), beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Reporting Person, Mr. Sherman or OMV LLC is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | ConversionSeries A Convertible Preferred Stock · Derivative | 99,748 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · derivative · entry 9 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By Orchestra Medical Ventures II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 99,748 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock is immediately convertible, at the option of the Reporting Person, into one share of common stock, par value $0.0001 per share (the "Common Stock"), of Motus GI Holdings, Inc. ("Motus"), and shall convert into Common Stock upon the occurrence of certain events. Please see the Motus Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-222441) (the "Registration Statement") for a complete description of the conversion rights. F6 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock is immediately convertible, at the option of the Reporting Person, into one share of common stock, par value $0.0001 per share (the "Common Stock"), of Motus GI Holdings, Inc. ("Motus"), and shall convert into Common Stock upon the occurrence of certain events. Please see the Motus Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-222441) (the "Registration Statement") for a complete description of the conversion rights. F2 · ownership.nature: The securities are directly held by Orchestra Medical Ventures II, L.P. ("OMV II"). Orchestra Medical Ventures II GP, LLC ("OMV GP") serves as general partner to OMV II. Reporting Person and Darren Sherman are the managing members of OMV GP. Reporting Person, together with Mr. Sherman, jointly exercises sole dispositive and sole voting power over the shares owned by OMV II. Each of Reporting Person, Mr. Sherman and OMV GP disclaims, for purposes of Section 16, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Reporting Person, Mr. Sherman or OMV GP is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | ConversionSeries A Convertible Preferred Stock · Derivative | 750 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · derivative · entry 8 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock is immediately convertible, at the option of the Reporting Person, into one share of common stock, par value $0.0001 per share (the "Common Stock"), of Motus GI Holdings, Inc. ("Motus"), and shall convert into Common Stock upon the occurrence of certain events. Please see the Motus Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-222441) (the "Registration Statement") for a complete description of the conversion rights. F6 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock is immediately convertible, at the option of the Reporting Person, into one share of common stock, par value $0.0001 per share (the "Common Stock"), of Motus GI Holdings, Inc. ("Motus"), and shall convert into Common Stock upon the occurrence of certain events. Please see the Motus Registration Statement filed with the Securities and Exchange Commission on Form S-1 (File No. 333-222441) (the "Registration Statement") for a complete description of the conversion rights. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | ConversionCommon Stock, par value $0.0001 per share | 65,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · nonDerivative · entry 5 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By Orchestra MOTUS Co-Investment Partners, LLC Disclosed balance after: 1,159,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.nature: The securities are directly held by Orchestra MOTUS Co-Investment Partners, LLC ("OMCP"). Orchestra Medical Ventures, LLC ("OMV LLC") serves as managing member to OMCP. Reporting Person and Darren Sherman are the managing partners of OMV LLC. Reporting Person, together with Mr. Sherman, jointly exercises sole dispositive and sole voting power over the shares owned by OMCP. Each of Reporting Person, Mr. Sherman and OMV LLC disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934 ("Section 16"), beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Reporting Person, Mr. Sherman or OMV LLC is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | ConversionCommon Stock, par value $0.0001 per share | 99,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · nonDerivative · entry 4 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By Orchestra Medical Ventures II, L.P. Disclosed balance after: 1,109,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: The securities are directly held by Orchestra Medical Ventures II, L.P. ("OMV II"). Orchestra Medical Ventures II GP, LLC ("OMV GP") serves as general partner to OMV II. Reporting Person and Darren Sherman are the managing members of OMV GP. Reporting Person, together with Mr. Sherman, jointly exercises sole dispositive and sole voting power over the shares owned by OMV II. Each of Reporting Person, Mr. Sherman and OMV GP disclaims, for purposes of Section 16, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Reporting Person, Mr. Sherman or OMV GP is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | PurchaseCommon Stock, par value $0.0001 per share | 40,000 | $5.00 | $200,000.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · nonDerivative · entry 3 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Indirect · By Orchestra Medical Ventures II, L.P. Disclosed balance after: 1,010,044 F1 · kind: The securities were purchased pursuant to an underwritten public offering by the Issuer. The offering closed on February 16, 2018. F2 · ownership.nature: The securities are directly held by Orchestra Medical Ventures II, L.P. ("OMV II"). Orchestra Medical Ventures II GP, LLC ("OMV GP") serves as general partner to OMV II. Reporting Person and Darren Sherman are the managing members of OMV GP. Reporting Person, together with Mr. Sherman, jointly exercises sole dispositive and sole voting power over the shares owned by OMV II. Each of Reporting Person, Mr. Sherman and OMV GP disclaims, for purposes of Section 16, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Reporting Person, Mr. Sherman or OMV GP is the beneficial owner of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | ConversionCommon Stock, par value $0.0001 per share | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · nonDerivative · entry 2 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 06:04 UTC | Motus GI Holdings, Inc. MOTS · Entity 93100 | PurchaseCommon Stock, par value $0.0001 per share | 75,000 | $5.00 | $375,000.00 |
DisclosureSEC source: 0001493152-18-002412 · form4.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · 10% owner · Chairman of the Board 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,250 F1 · kind: The securities were purchased pursuant to an underwritten public offering by the Issuer. The offering closed on February 16, 2018. Read SEC document |
| November 15, 2017 Filed Nov 16, 2017 08:54 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 5,000 | $6.55 | $32,750.00 |
DisclosureSEC source: 0001209191-17-061052 · doc4.xml · nonDerivative · entry 5 Hochman David P · CIK 0001292834 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NSH 2008 Family Trust Disclosed balance after: 220,000 Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 10:56 UTC Amendment | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 5,000 | $6.90 | $34,500.00 |
DisclosureSEC source: 0001209191-17-060534 · doc4a.xml · nonDerivative · entry 5 Hochman David P · CIK 0001292834 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NSH 2008 Family Trust Disclosed balance after: 215,000 F1 · kind: The transaction code in Column 3 reported on the Form 4 filed on November 14, 2017 was incorrectly stated as "A" and is being corrected herein via this filing. Read SEC document |
| November 13, 2017 Filed Nov 14, 2017 09:15 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantCommon Stock | 5,000 | $6.90 | $34,500.00 |
DisclosureSEC source: 0001209191-17-060502 · doc4.xml · nonDerivative · entry 5 Hochman David P · CIK 0001292834 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NSH 2008 Family Trust Disclosed balance after: 215,000 Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 10:33 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 10,000 | $7.08 | $70,800.00 |
DisclosureSEC source: 0001209191-17-060177 · doc4.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,500 Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:36 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 30,500 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0001209191-17-035844 · doc4.xml · derivative · entry 1 Hochman David P · CIK 0001292834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,500 Underlying: Common Stock · 30,500 shares Expires 2027-05-25 F1 · deemedExecutionDate: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. The option will vest in equal monthly installments over the course of 12 months beginning on the date of grant. Read SEC document |
| May 11, 2017 Filed May 12, 2017 11:15 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 3,400 | $6.18 | $21,012.00 |
DisclosureSEC source: 0001209191-17-031751 · doc4.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,500 Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 21:57 UTC | NAKED BRAND GROUP INC. NAKD · Entity 166704 | GrantEmployee Stock Option (right to buy) · Derivative | 1,200,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001144204-17-014863 · v461968_4.xml · derivative · entry 1 Hochman David P · CIK 0001292834 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Carole S. Hochman Trust Disclosed balance after: 1,200,000 Underlying: Common Stock · 1,200,000 shares Expires 2021-03-13 F1 · ownership.nature: The reporting person and an immediate family member are beneficiaries of the Carole S. Hochman Trust. The reporting person is also one of two trustees of the Carole S. Hochman Trust. Read SEC document |
| January 12, 2017 Filed Jan 17, 2017 18:15 UTC | NAKED BRAND GROUP INC. NAKD · Entity 166704 | Exercise / conversionConvertible Promissory Note · Derivative | Not disclosed | $0.00 Strike: $1.04 | $12,210.09 |
DisclosureSEC source: 0001144204-17-002492 · v456996_4.xml · derivative · entry 4 Hochman David P · CIK 0001292834 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 11,740 shares Expires 2017-01-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · reported_value: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. F1 · price: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. F1 · derivative.exercise_date: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. F1 · derivative.expiration_date: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. F1 · derivative.underlying_shares: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. Read SEC document |
| January 12, 2017 Filed Jan 17, 2017 18:15 UTC | NAKED BRAND GROUP INC. NAKD · Entity 166704 | GrantConvertible Promissory Note · Derivative | Not disclosed | $12,000.00 Strike: $1.04 | $12,210.09 |
DisclosureSEC source: 0001144204-17-002492 · v456996_4.xml · derivative · entry 3 Hochman David P · CIK 0001292834 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 11,740 shares Expires 2017-01-12 F1 · reported_value: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. F1 · derivative.exercise_date: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. F1 · derivative.expiration_date: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. F1 · derivative.underlying_shares: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. F1 · valueOwnedAfter: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. Read SEC document |
| January 12, 2017 Filed Jan 17, 2017 18:15 UTC | NAKED BRAND GROUP INC. NAKD · Entity 166704 | GrantCommon Stock | 11,740 | $1.04 | $12,209.60 |
DisclosureSEC source: 0001144204-17-002492 · v456996_4.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,721 F1 · shares: On November 3, 2016, the reporting person purchased a 9% convertible promissory note for $12,000 (the "Note") that was convertible into shares of common stock . On January 12, 2017, in connection with the completion of the Qualified Financing (as defined in the Note), the outstanding balance of the Note, including principal and accrued interest of $12,000 and $210.09, respectively, automatically converted into 11,740 shares of common stock at a conversion price per share of $1.04. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 10:23 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | PurchaseCommon Stock | 10,000 | $7.00 | $69,960.00 |
DisclosureSEC source: 0001209191-16-151350 · doc4.xml · nonDerivative · entry 1 Hochman David P · CIK 0001292834 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 456,100 Read SEC document |
| September 16, 2016 Filed Sep 20, 2016 16:55 UTC | Corbus Pharmaceuticals Holdings, Inc. CRBP · Entity 6261 | GrantStock Option(right to buy) · Derivative | 50,000 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001209191-16-142167 · doc4.xml · derivative · entry 1 Hochman David P · CIK 0001292834 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Orchestra Medical Ventures, LLC of which David Hochman is the Managing Partner Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2026-09-16 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan and 50% of the option award will vest on the three-month anniversary of the date of grant with the remainder of the option award vesting on the six-month anniversary of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.